[New antimicrobial agent series XXXVII: potassium clavulanate/Ticarcillin sodium].
Fujimori
I
I
D000818:Animals; D001419:Bacteria / Q000187:drug effects* / Q000201:enzymology; D001424:Bacterial Infections / Q000188:drug therapy* / Q000378:metabolism; D019818:Clavulanic Acid; D002969:Clavulanic Acids / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004359:Drug Therapy, Combination / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D013982:Ticarcillin / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D014018:Tissue Distribution; D001618:beta-Lactamases / Q000096:biosynthesis
D002969:Clavulanic Acids; D019818:Clavulanic Acid; D001618:beta-Lactamases; D013982:Ticarcillin